European Growth Companies With High Insider Ownership In February 2026

European Growth Companies With High Insider Ownership In February 2026

Simply Wall St

Thu, February 19, 2026 at 2:35 PM GMT+9 4 min read

In this article:

OTGLF

-14.25%

HSHP

+3.47%

VIMGF

+62.45%

MILDEF.ST

+3.71%

KEBNI-B.ST

-5.57%

As of February 2026, the European markets have experienced volatility, with the pan-European STOXX Europe 600 Index reaching new highs but ending the week with only a slight gain amid concerns about AI disruption and strong U.S. job data. In this fluctuating environment, growth companies with high insider ownership can offer potential resilience and alignment of interests between management and shareholders, making them intriguing options for investors looking to navigate these uncertain times.

Top 10 Growth Companies With High Insider Ownership In Europe

Name Insider Ownership Earnings Growth
Warimpex Finanz- und Beteiligungs (WBAG:WXF) 25.9% 100.6%
MilDef Group (OM:MILDEF) 13.7% 34.9%
KebNi (OM:KEBNI B) 34.9% 80.1%
Hanza (OM:HANZA) 24.4% 48.9%
Devyser Diagnostics (OM:DVYSR) 29.6% 68.3%
CTT Systems (OM:CTT) 17.5% 42.7%
Clavister Holding AB (publ.) (OM:CLAV) 18% 116.2%
Circus (XTRA:CA1) 21.9% 79.4%
CD Projekt (WSE:CDR) 29.7% 43.2%
Bonesupport Holding (OM:BONEX) 10.3% 58.7%

Click here to see the full list of 213 stocks from our Fast Growing European Companies With High Insider Ownership screener.

Let’s uncover some gems from our specialized screener.

Himalaya Shipping

Simply Wall St Growth Rating: ★★★★★☆

Overview: Himalaya Shipping Ltd. offers dry bulk shipping services globally and has a market cap of NOK5.72 billion.

Operations: The company generates revenue primarily through its transportation and shipping segment, which amounted to $131.90 million.

Insider Ownership: 30.4%

Himalaya Shipping demonstrates potential as a growth company with high insider ownership in Europe. Despite slower revenue growth at 7.1% annually, its earnings are forecast to grow significantly, outpacing the Norwegian market. Recent financial results show substantial improvement, with Q4 2025 net income rising to US$13.5 million from US$1.1 million year-on-year. Though interest payments aren’t well-covered by earnings, strong future earnings projections and strategic time charter agreements bolster its growth prospects amidst fluctuating dividend distributions.

Click here to discover the nuances of Himalaya Shipping with our detailed analytical future growth report.
Our valuation report here indicates Himalaya Shipping may be overvalued.

OB:HSHP Earnings and Revenue Growth as at Feb 2026

Vimian Group

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Vimian Group AB operates in the global animal health industry and has a market capitalization of SEK14.04 billion.

Operations: The company’s revenue is derived from its Medtech segment (€155.50 million), Diagnostics segment (€22.90 million), Specialty Pharma segment (€182.40 million), and Veterinary Services segment (€64.50 million).

Story Continues  

Insider Ownership: 12.7%

Vimian Group’s earnings are projected to grow significantly at 28% annually, surpassing the Swedish market. Although revenue growth is moderate at 8.7%, recent financials show a full-year sales increase to €425 million from €374.8 million, with net income rising to €31.3 million from €18.5 million year-on-year. Trading below fair value by 21.9% and analysts forecasting a price rise of 27%, Vimian’s growth potential remains robust despite low forecasted return on equity at 9.2%.

Click here and access our complete growth analysis report to understand the dynamics of Vimian Group.
Our expertly prepared valuation report Vimian Group implies its share price may be lower than expected.

OM:VIMIAN Earnings and Revenue Growth as at Feb 2026

Idorsia

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Idorsia Ltd is a biopharmaceutical company focused on discovering, developing, and commercializing drugs for unmet medical needs across Switzerland, the United States, Japan, Europe, China, and Canada with a market cap of CHF998.48 million.

Operations: The company’s revenue is primarily generated from its activities in discovering, developing, and commercializing drugs, amounting to CHF232.51 million.

Insider Ownership: 24.5%

Idorsia is poised for significant growth, with earnings forecasted to expand 64.6% annually as it transitions to profitability within three years. Despite a volatile share price and past shareholder dilution, its revenue growth of 19.1% outpaces the Swiss market average. Recent developments include a Phase 3 program for lucerastat targeting Fabry disease and an exclusive agreement with EMS S.A. to distribute QUVIVIQ in Latin America, highlighting Idorsia’s strategic expansion efforts and innovative pipeline potential.

Unlock comprehensive insights into our analysis of Idorsia stock in this growth report.
Insights from our recent valuation report point to the potential overvaluation of Idorsia shares in the market.

SWX:IDIA Ownership Breakdown as at Feb 2026

Next Steps

Navigate through the entire inventory of 213 Fast Growing European Companies With High Insider Ownership here.
Want To Explore Some Alternatives? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years._

Companies discussed in this article include OB:HSHP OM:VIMIAN and SWX:IDIA.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin